Irbesartan + Hidroclorotiazida Alter Genéricos (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide is used to manage cardiovascular conditions that involve elevated blood pressure and fluid overload.

• Hypertension: lowers systolic and diastolic blood pressure by blocking angiotensin II–mediated vasoconstriction and by increasing urinary sodium and water excretion.
• Edema: decreases peripheral fluid accumulation through the diuretic action of hydrochlorothiazide, aiding in the reduction of swelling associated with heart or kidney disease.
• Chronic kidney disease with hypertension: helps control systemic blood pressure and may attenuate protein loss in the urine, supporting renal protection in patients with impaired kidney function.

• Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal cells, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule, inhibiting the Na⁺‑Cl⁻ cotransporter, which reduces sodium and chloride reabsorption, increases urinary output, and lowers plasma volume. The combined actions produce additive antihypertensive and diuretic effects through complementary mechanisms.

Irbesartan/Hydrochlorothiazide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: feeling of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Increased urination: more frequent need to void due to diuretic effect.

Serious or Rare Side Effects

• Severe dehydration: excessive fluid loss leading to low blood pressure.
• Hyperkalemia: elevated potassium that can affect heart rhythm.
• Angioedema: swelling of face, lips, tongue or throat requiring immediate care.

When prescribing Irbesartan/Hydrochlorothiazide, several precautions should be observed to ensure patient safety.

• Monitor blood pressure: check regularly to avoid hypotension.
• Assess electrolytes: watch for potassium and sodium disturbances.
• Evaluate renal function: test creatinine and eGFR before and during therapy.
• Avoid use in pregnancy: drug is classified Category D and may harm the fetus.
• Use caution in elderly: increased sensitivity to blood pressure changes and dehydration.
• Store at room temperature: keep in the original container, protect from moisture and light.

Irbesartan/Hydrochlorothiazide can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: risk of dangerous hyperkalemia.
• ACE inhibitors or aliskiren: additive effects on potassium and renal function.
• Lithium: increased lithium levels and toxicity.
• NSAIDs: may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may cause additive hypotension.
• Antidiabetic agents: blood glucose may decrease, requiring dose adjustment.
• Corticosteroids: can increase sodium retention counteracting diuretic action.